MSLN expression	Solid Tumor	MSLN expression	Solid Tumor	BAY 94-9343 Sensitive: C2 – Inclusion Criteria BAY 94-9343 Sensitive : C2	BAY 94-9343 Sensitive: C2 – Inclusion Criteria BAY 94-9343 Sensitive : C2
MSLN expression	Ovarian Cancer	MSLN expression	Ovarian Cancer	RG7600 Sensitive: C4 – Case Studies RG7600 Sensitive : C4	RG7600 Sensitive: C4 – Case Studies RG7600 Sensitive : C4
MSLN expression	Pancreatic Cancer	MSLN expression	Pancreatic Cancer	RG7600 Sensitive: C4 – Case Studies RG7600 Sensitive : C4	RG7600 Sensitive: C4 – Case Studies RG7600 Sensitive : C4
MSLN expression	Thymic Carcinoma	MSLN expression	Thymic Carcinoma	BAY 94-9343 Sensitive: D – Preclinical BAY 94-9343 Sensitive : D	BAY 94-9343 Sensitive: D – Preclinical BAY 94-9343 Sensitive : D
MSLN overexpression	Acute Myelogenous Leukemia	MSLN overexpression	Acute Myelogenous Leukemia	BAY 94-9343 Sensitive: D – Preclinical BAY 94-9343 Sensitive : D	BAY 94-9343 Sensitive: D – Preclinical BAY 94-9343 Sensitive : D
MSLN expression	Ovarian Cancer	MSLN expression	Ovarian Cancer	MORAb-109 Sensitive: D – Preclinical MORAb-109 Sensitive : D	MORAb-109 Sensitive: D – Preclinical MORAb-109 Sensitive : D
FOSL1 expression	Ovarian Cancer	FOSL1 expression	Ovarian Cancer	MORAb-109 Sensitive: D – Preclinical MORAb-109 Sensitive : D	MORAb-109 Sensitive: D – Preclinical MORAb-109 Sensitive : D

Mesothelin-targeted antibody-drug conjugate

Associations(7)